

Christine E. Staatsz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4595726/christine-e-staatz-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97
papers

4,056
citations

31
h-index

62
g-index

101
ext. papers

4,604
ext. citations

3.8
avg. IF

5.7
L-index

#	Paper	IF	Citations
97	Comparison of free plasma versus saliva mycophenolic acid exposure following mycophenolate mofetil administration in adult kidney transplant recipients. <i>Clinical Biochemistry</i> , 2021 , 100, 78-78	3.5	1
96	Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 2021 , 42, 94-102	1.7	
95	Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2021 , 12, 635165	5.6	2
94	Evaluation of Bayesian Forecasting Methods for Prediction of Tacrolimus Exposure Using Samples Taken on Two Occasions in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 238-246	3.2	0
93	Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats. <i>Xenobiotica</i> , 2021 , 51, 811-817	2	4
92	Evaluating the utilisation and expenditure patterns of erythropoietin stimulating agents and immunosuppressants in Australian chronic kidney disease patients. <i>Journal of Pharmaceutical Health Services Research</i> , 2021 , 12, 350-356	1	
91	Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents. <i>Toxicology and Applied Pharmacology</i> , 2021 , 410, 115339	4.6	
90	Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 17-51	6.2	9
89	Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. <i>Xenobiotica</i> , 2021 , 51, 194-201	2	
88	Kidney transplant recipient's perceptions of blood testing through microsampling and venepuncture. <i>Bioanalysis</i> , 2020 , 12, 873-881	2.1	4
87	Investigation of the Association Between Total and Free Plasma and Saliva Mycophenolic Acid Concentrations Following Administration of Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients. <i>Clinical Drug Investigation</i> , 2019 , 39, 1175-1184	3.2	6
86	Quizzing for success: Evaluation of the impact of feedback quizzes on the experiences and academic performance of undergraduate students in two clinical pharmacokinetics courses. <i>Currents in Pharmacy Teaching and Learning</i> , 2019 , 11, 742-749	1.5	12
85	Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients. <i>Translational Andrology and Urology</i> , 2019 , 8, S198-S213	2.3	9
84	An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2436-2441	3.8	17
83	Pharmacometrics in Australasia-Twenty Years of Population Approach Group of Australia and New Zealand. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 701-704	4.5	1
82	Prednisolone Concentrations in Plasma (Total and Unbound) and Saliva of Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 755-760	3.2	2
81	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , 2019 , 103, 2012-2030	1.8	19

80	Investigating barriers to immunosuppressant medication adherence in renal transplant patients. <i>Nephrology</i> , 2019 , 24, 102-110	2.2	23
79	Patterns in use and costs of subsidising 5-aminosalicylic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia. <i>Digestive and Liver Disease</i> , 2018 , 50, 314-317	3.3	
78	Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 195-201	3.2	5
77	Antimicrobial stewardship in paediatric oncology: Impact on optimising gentamicin use in febrile neutropenia. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26810	3	5
76	Comparison of methods to estimate glomerular filtration rate in paediatric oncology patients. <i>Journal of Paediatrics and Child Health</i> , 2018 , 54, 141-147	1.3	6
75	Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?. <i>Drugs in R and D</i> , 2018 , 18, 271-282	3.4	3
74	Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit. <i>Drug Safety</i> , 2018 , 41, 1023-1033	5.1	6
73	Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 639-667	5.1	20
72	A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	11
71	Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients. <i>AAPS Journal</i> , 2017 , 20, 14	3.7	2
70	Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2017 , 3, e171	2.3	3
69	Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017 , 42, 993-1004	2.7	7
68	Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 907-912	2.2	3
67	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 206-14	5.9	11
66	Gentamicin Pharmacokinetics and Monitoring in Pediatric Patients with Febrile Neutropenia. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 693-698	3.2	6
65	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Medicine</i> , 2016 , 42, 1535-1545	14.5	172
64	Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. <i>Annals of Transplantation</i> , 2016 , 21, 1-11	1.4	12
63	Gentamicin Pharmacokinetics and Monitoring in Pediatric Febrile Neutropenic Patients. <i>Therapeutic Drug Monitoring</i> , 2016 , 1	3.2	2

62	Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3407-14	5.9	20
61	Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1295-1335	6.2	51
60	Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the UK. <i>Journal of Pharmacy Practice and Research</i> , 2016 , 46, 15-21	0.7	10
59	Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 993-1025	6.2	64
58	Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients. <i>American Journal of Clinical Pathology</i> , 2015 , 143, 514-26	1.9	3
57	Genetics and nonmelanoma skin cancer in kidney transplant recipients. <i>Pharmacogenomics</i> , 2015 , 16, 161-72	2.6	6
56	Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients. <i>Clinical Drug Investigation</i> , 2015 , 35, 743-50	3.2	5
55	Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 409-21	6.2	26
54	Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1475-6	3.8	2
53	Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1064-75	3.8	10
52	Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. <i>Clinical Drug Investigation</i> , 2014 , 34, 183-8	3.2	6
51	How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 227-245	6.2	9
50	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 509-23	3.8	58
49	Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. <i>Archives of Toxicology</i> , 2014 , 88, 1351-89	5.8	115
48	Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 442-7	3.2	18
47	Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 62-70	3.2	56
46	Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 303-31	6.2	47
45	Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. <i>Clinical Pharmacokinetics</i> , 2013 , 52, 289-301	6.2	47

44	PharmGKB summary: cyclosporine and tacrolimus pathways. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 563-85	1.9	137
43	A differential impact of mycophenolic acid, prednisolone, and tacrolimus exposure on sCD30 levels in adult kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 240-5	3.2	3
42	Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. <i>Transplant International</i> , 2012 , 25, 1182-93	3	28
41	Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 711-41	6.2	67
40	A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients. <i>Nephrology</i> , 2012 , 17, 294-9	2.2	13
39	NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. <i>Transplantation</i> , 2012 , 94, 1025-32	1.8	35
38	Once- versus twice-daily tacrolimus: are the formulations truly equivalent?. <i>Drugs</i> , 2011 , 71, 1561-77	12.1	78
37	Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 759-72	6.2	26
36	BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. <i>Journal of Transplantation</i> , 2011 , 2011, 750836	2.3	20
35	Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 207-23	3.8	33
34	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011 , 25, 47-57	3.3	89
33	Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 1243-52	2.8	14
32	Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 663-72	3.2	29
31	Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation. <i>Nephrology</i> , 2010 , 15, 522-32	2.2	10
30	Pharmacogenetic influences on mycophenolate therapy. <i>Pharmacogenomics</i> , 2010 , 11, 369-90	2.6	42
29	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 141-75	6.2	246
28	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 207-21	6.2	148
27	Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trials. <i>Transplantation</i> , 2010 , 90, 44-51	1.8	18

26	Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 723-33	3.2	21
25	A comparison of mycophenolate use in Australia and Northern Europe, and the impact on the pharmaceutical benefits scheme. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 386-92	2.6	1
24	Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 1050-7	5.1	97
23	Therapeutic monitoring of mycophenolate in transplantation: is it justified?. <i>Current Drug Metabolism</i> , 2009 , 10, 179-87	3.5	30
22	Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 457-66	3.2	34
21	Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 67-74	3.2	38
20	Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 13-58	6.2	406
19	Predictors of new onset diabetes after renal transplantation. <i>Clinical Transplantation</i> , 2007 , 21, 136-43	3.8	75
18	Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. <i>Pharmaceutical Research</i> , 2007 , 24, 2187-97	4.5	249
17	Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006 , 31, 17-25	2.2	8
16	Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 164-76	3.8	30
15	Tacrolimus in Patients with Rheumatoid Arthritis. <i>Drugs</i> , 2005 , 65, 1002-1003	12.1	
14	Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. <i>Drugs and Aging</i> , 2005 , 22, 541-57	4.7	44
13	Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 507-16	2.8	57
12	A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. <i>Liver Transplantation</i> , 2004 , 10, 506-12	4.5	24
11	Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 623-53	6.2	562
10	Sampling times for monitoring tacrolimus in stable adult liver transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 593-9	3.2	18
9	Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 158-66	3.2	15

8	Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. <i>Liver Transplantation</i> , 2003 , 9, 130-7	4.5	56
7	Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 597-605	2.8	12
6	Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 660-9	6.1	110
5	Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 607-15	3.2	37
4	Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 1905-9	4.3	108
3	Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. <i>Transplantation</i> , 2001 , 72, 1056-61	1.8	32
2	Identifying Drug-Related Readmissions Is There a Better Way of Assessing the Contribution of Adverse Medication Events?. <i>Journal of Pharmacy Practice and Research</i> , 2000 , 30, 47-53		7
1	Ester prodrugs of a potent analgesic, morphine-6-sulfate: syntheses, spectroscopic and physicochemical properties. <i>International Journal of Pharmaceutics</i> , 1998 , 163, 177-190	6.5	11